Identification and characterization of somatic steroid 5α-reductase (SRD5A2) mutations in human prostate cancer tissue

Oncogene

Volumn 23, Issue 44, 2004, Pages 7399-7405

  Makridakis, Nick ^a   Akalu, Abebe ^a,c   Reichardt, Juergen K V ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b IGM240 ^*  (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen metabolism; Pharmacogenetics; Prostate cancer; Somatic mutations; Steroid 5 reductase

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; N [2,2,2 TRIFLUORO 1 PHENYL 1 (TRIFLUOROMETHYL)ETHYL] 3 OXO 4 AZA 5ALPHA ANDROST 1 ENE 17BETA CARBOXAMIDE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER GROWTH; CANCER TISSUE; CATALYSIS; CONTROLLED STUDY; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; HUMANS; MALE; MUTATION; MUTATION, MISSENSE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATE; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

ANIMALIA;

EID: 6044274394     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207922     Document Type: Article

References (22)

1. Akalu A, Elmajian DA, Highshaw RA, Nichols PW and Reichardt JKV. (1999). J. Urol., 161, 1355-1358.
2. Akalu A and Reichardt JKV. (1999). Genet. Anal., 15, 229-233.
3. Brothman AR, Peehl DM, Patel AM and McNeal JE. (1990). Cancer Res., 50, 3795-3803.
4. Cheng E, Lee C and Grayhack J. (1993). Prostate Diseases Lepor H and RK Lawson (eds). W.B. Saunders: Philadelphia, PA, pp. 57-71.
5. di Salle E, Giudici D, Radice A, Zaccheo T, Ornati G, Nesi M, Panzeri A and De los PM. (1998). J. Steroid. Biochem. Mol. Biol., 64, 179-186.
6. Frye SV, Bramson HN, Herman DJ, Lee FW, Sinhababu AK and Tian G. (1998). Pharm. Biotechnol., 11, 393-422.
7. Gottlieb B, Beitel LK, Lumbroso R, Pinsky L and Trifiro M. (1999). Hum. Mutat., 14, 103-114.
8. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ. (2003). CA Cancer J. Clin., 53, 5.
9. Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RI, Kantoff PW, Loda M, Meyerson M and Sellers WR. (2003). Cancer Res., 63, 4781-4785.
10. Luo J, Dunn TA, Ewing CM, Walsh PC and Isaacs WB. (2003). Prostate, 57, 134-139.
11. Macoska JA, Powell IJ, Sakr W and Lane MA. (1992). J. Urol., 147, 1142-1146.
12. Makridakis NM, di Salle E and Reichardt JKV. (2000). Pharmacogenetics, 10, 407-413.
13. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi C-Y, Yu MC, Henderson BE and Reichardt JKV. (1997). Cancer Res., 57, 1020-1022.
14. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE and Reichardt JKV. (1999). Lancet, 354, 975-978.
15. Nelson DL and Cox MM. (2000). Lehninger Principles of Biochemistry 3rd Edn., Ryan M, Strange L and Neal V (eds). Worth Publishers: New York, NY, pp. 257-269.
16. Ross RK, Pike MC, Coetzee GA, Reichardt JKV, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN and Henderson BE. (1998). Cancer Res., 58, 4497-4504.
17. Schroder FH, Hermanek P, Denis L, Fair DR, Gospodarowicz MK and Pavone-Maculaso M. (1992). Prostate, 4, 129-138.
18. Stoner E. (1996). Prostate, 6, 82-87.
19. Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke A, Wilson JD and Russell DW. (1992). J. Clin. Invest., 90, 799-809.
20. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM and Coltman Jr CA. (2003). N. Engl. J. Med., 349, 215-224.
21. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J and Kallioniemi OP. (1995). Nat. Genet., 9, 401-406.
22. Wigley WC, Prihoda JS, Mowszowicz I, Mendonca BB, New MI, Wilson JD and Russell DW. (1994). Biochem., 33, 1265-1270.